



Match Overview

| | | |
|---|--|----|
| 1 | Crossref 32 words Tatjana Nikolic, Jaap J Zwaginga, Bas S Uitbeijerse, Nic ky J Woittiez, Eelco J de Koning, Henk-Jan Aanstoot, Bart | 1% |
| 2 | Crossref 32 words Tomoko Hayashi, Shiyin Yao, Brian Crain, Victor J. Prom essi et al. "Induction of Tolerogenic Dendritic Cells by a..." | 1% |
| 3 | Crossref 31 words Torres-Aguilar, H.. "Tolerogenic dendritic cells in autoim mune diseases", <i>Autoimmunity Reviews</i> , 201011 | 1% |
| 4 | Internet 29 words crawled on 16-May-2020 worldwidescience.org | 1% |
| 5 | Crossref 29 words Silvia Rodriguez-Fernandez, Irma Pujol-Autonell, Ferran Brianso, David Perna-Barrull et al. "Phosphatidylserine- | 1% |
| 6 | Internet 25 words crawled on 15-Jan-2021 www.touchendocrinology.com | 1% |
| | Crossref 23 words | |

Name of Journal: *World Journal of Diabetes*

Manuscript NO: 62449

Manuscript Type: MINIREVIEWS

Current advances in using tolerogenic dendritic cells as a therapeutic alternative in the treatment of type 1 diabetes

Updating tolDC therapy for T1D treatment

13 William de Jesús Ríos-Ríos, Sorely Adelina Sosa-Luis, Honorio Torres-Aguilar



ALL

IMAGES

VIDEOS

59,200 Results

Any time ▾

[Tolerogenic dendritic cells as a therapy for treating ...](#)

<https://www.sciencedirect.com/science/article/pii/S1521661613001216>

Aug 01, 2013 · Furthermore, the use of tolerogenic DCs to treat autoimmune diseases has already been explored in **type 1 diabetes** mellitus. Giannoukakis, et al. conducted a randomized placebo-controlled trial to evaluate the safety of autologous tolerogenic DCs in 10 patients with **type 1 diabetes** mellitus . Tolerogenic DCs were generated using anti-sense oligonucleotides for CD40, CD80, and ...

Cited by: 26

Author: Carolina Llanos, Juan Pablo Mackern-Ob...

Publish Year: 2013

[Current Paradigms of Tolerogenic Dendritic Cells and ...](#)

<https://www.mdpi.com/2073-4409/8/10/1291/htm> ▾

Tolerogenic dendritic cells (tolDCs) are central players in the initiation and maintenance of immune tolerance and subsequent prevention of autoimmunity. Recent advances in treatment of autoimmune diseases including systemic lupus erythematosus (SLE) have focused on inducing specific tolerance to avoid long-term use of immunosuppressive drugs. Therefore, DC-targeted therapies to either ...

Cited by: 4

Author: Patcharee Ritprajak, Chamraj Kaewraemr...

Publish Year: 2019

[Clinical Use of Tolerogenic Dendritic Cells-Harmonization ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706930>

1. The Case for Cell-Based Therapy in Autoimmunity, Allergy, and Transplantation. The healthy immune system is well balanced to protect against invading harmful pathogens or cancerous cells, whilst maintaining a state of unresponsiveness ("tolerance") to our self-tissues and harmless substances [].Breakdown of immunological tolerance can lead to unwanted, detrimental reactions that cause ...

Cited by: 64

Author: Anja Ten Brinke, Catharien M. U. Hilkens,...

Publish Year: 2015

[Tolerogenic dendritic cell-based treatment for multiple ...](#)

<https://bmjopen.bmj.com/content/9/9/e030309> ▾

Sep 01, 2019 · The use of cryopreserved tolerogenic dendritic cells (tolDC) allows production of batches of tolDC, stored in ready-to-use aliquots for the required administrations during the treatment period, thereby reducing variability and global production cost.

Cited by: 9

Author: Barbara Willekens, Silvia Presas-Rodríguez



Current Paradigms of Tolerogenic Dendritic Cells and ...

<https://pubmed.ncbi.nlm.nih.gov/31640263>

Tolerogenic dendritic cells (tolDCs) are central players in the initiation and maintenance of immune tolerance and subsequent prevention of autoimmunity. Recent advances in treatment of autoimmune diseases including systemic lupus erythematosus (SLE) have focused on inducing specific tolerance to avoid long-term use of immunosuppressive drugs.

Cited by: 6

Author: Patcharee Ritprajak, Chamraj Kaewraemr...

Publish Year: 2019

Generation and characterisation of therapeutic tolerogenic ...

<https://pubmed.ncbi.nlm.nih.gov/20551157>

Objectives: Tolerogenic dendritic cells (tolDCs) constitute a promising experimental treatment for targeting autoreactive T cells in autoimmune diseases, including rheumatoid arthritis (RA). The authors' goal is to bring tolDC therapy for RA to the clinic. Here the authors address key translational issues related to the manufacturing of tolDCs from RA patients with current good manufacturing ...

Cited by: 193

Author: Rachel A Harry, Amy E Anderson, John ...

Publish Year: 2010

Current Paradigms of Tolerogenic Dendritic Cells and ...

<https://www.mdpi.com/2073-4409/8/10/1291> ▾

Tolerogenic dendritic cells (tolDCs) are central players in the initiation and maintenance of immune

Search Tools

Turn off Hover Translation (关闭取词)

激活 Windows

转到“设置”以激活 Windows。

[ALL](#)[IMAGES](#)[VIDEOS](#)[MAPS](#)[NEWS](#)[SHOPPING](#)[TOOLS](#)

[Clinical Tolerogenic Dendritic Cells: Exploring ...](#)

<https://pubmed.ncbi.nlm.nih.gov/29075262>

Tolerogenic dendritic cell (tDC)-based clinical trials for the **treatment** of autoimmune diseases are now a reality. Clinical trials are currently exploring the effectiveness of tDC to treat autoimmune diseases of **type 1 diabetes** mellitus, rheumatoid arthritis, multiple sclerosis (MS), and Crohn's disease.

Cited by: 59

Author: Brett Eugene Phillips, Yesica Garciafiguero...

Publish Year: 2017

[Phase I \(safety\) study of autologous tolerogenic dendritic ...](#)

<https://pubmed.ncbi.nlm.nih.gov/21680720>

Treatment with autologous **dendritic cells**, in a native state or directed ex vivo toward a **tolerogenic** immunosuppressive state, is safe and well tolerated. **Dendritic cells** upregulated the frequency of a potentially beneficial B220+ CD11c- B-cell population, at least in **type 1 diabetes** autoimmunity.

Cited by: 430

Author: Nick Giannoukakis, Brett E. Phillips, David F...

Publish Year: 2011

[Phase I \(safety\) study of autologous tolerogenic dendritic ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/21680720>

CONCLUSIONS: **Treatment** with autologous **dendritic cells**, in a native state or directed ex vivo toward a **tolerogenic** immunosuppressive state, is safe and well tolerated. **Dendritic cells** upregulated the frequency of a potentially beneficial B220+ CD11c- B-cell population, at least in **type 1 diabetes** ...

Cited by: 430

Author: Nick Giannoukakis, Brett E. Phillips, David F...

Publish Year: 2011

[Therapeutic induction of tolerogenic dendritic cells via ...](#)

<https://www.sciencedirect.com/science/article/pii/S0952791521000054>

Therapeutic induction of **tolerogenic dendritic cells** via aryl hydrocarbon receptor signaling. Dendritic cells (DCs) are potent antigen-presenting cells (APCs), which sample the exogenous and endogenous cues to control adaptive immunity, balancing effector and ...

Author: Andreia Barroso, João V Mahler, Pedro ...

Publish Year: 2021

[It's Time to Bring Dendritic Cell Therapy to Type 1 Diabetes](#)

<https://diabetes.diabetesjournals.org/content/63/1/20>

Jan 01, 2014 · The approach reviewed here consists of developing a personalized **therapy** using the